Seropeutics is a biopharmaceutical company developing drug platforms to treat neuropsychiatric diseases such as Autism Spectrum Disorder (ASD) and Binge Eating Disorder (BED). Evidence from several different animal studies has determined that activating specific serotonin receptors causes significantly reduced repetitive behavioral symptoms associated with such disorders and improves social interaction in patients with ASD.

**Technology**

Seropeutics treats ASD and binge eating by activating specific serotonin receptors that are usually deactivated in these neuropsychiatric disorders. Evidence from three different animal studies supports Seropeutics’ drug platform for ASD. From those studies, Seropeutics has determined that activating specific serotonin receptors causes significantly reduced stereotypy and improved social interaction in patients with ASD. (Stereotypy is a repetitive and rhythmic but contextually inappropriate and purposeless movement or behavior. No drug on the market can treat stereotypy.) Other animal models support Seropeutics’ drug platform for binge eating. Animal models have shown that overeating is significantly reduced when a different serotonin receptor is activated. By activating this specific serotonin receptor, Seropeutics can treat binge eating. Currently, only one drug is approved to treat binge eating, and it demonstrates significant side effects and addiction risk in patients. Seropeutics’ drug platforms that target specific serotonin receptors offer therapy for autism and binge eating.

**Market Potential**

Seropeutics’ drug platforms target two significant markets, autism and binge eating. Autism is the fastest-growing developmental disability in the US. More than 3.5 million Americans have ASD; nearly 10 percent of those diagnosed are pediatric patients. Approximately 2.8 million people in the US suffer from binge eating. In addition, Seropeutics’ platforms have the potential to treat other neurological disorders such as psychosis, schizophrenia, attention deficit hyperactivity disorder, dementia, and addiction.

**Strategy**

Seropeutics is raising a Series A round of $15 million to advance its two lead compounds through Phase I. Series B will enable the company to establish proof of concept in humans, and once established, it will pursue either an IPO or a pharmacy licensing strategy. The market strategy includes a plan to recruit a pharmaceutical company after Phase 1B to partner on an anti-psychotic indication, which
will require large trials and a strong distribution capability. As funding permits, the company can pursue other indications since its two chemotype platforms provide multiple drug candidates for many neuropsychiatric indications.

**Management Team**

**Donald R. Kiepert, Founder and Executive Chairman**
Donald Kiepert is an experienced pharmacist, CEO, and entrepreneur who has started 12 successful life science companies. He recently served as an advisor to Bain Capital and Chairman and CEO of Touchstone Services. Previously, he served in roles as Founder, Chairman, and CEO of Point Therapeutics, Lantheus Medical Imaging, and CEO of Chartwell Home Therapies. Mr. Kiepert received both his Bachelor’s and Master’s degrees in Pharmaceutics from Purdue University.

**Raymond G. Booth, Ph.D., Founding Inventor**
Raymond Booth is a Professor in the Department of Chemistry & Chemical Biology and the Department of Pharmaceutical Sciences at Northeastern University. He is also the Associate Director of the Center for Drug Discovery. Dr. Booth has over 30 years’ experience in serotonin drug discovery at UCSF, Harvard Medical School, and the University of Florida. Dr. Booth received his Ph.D. in Pharmaceutical Sciences from the University of California at San Francisco.

**Contact Information**
Donald Kiepert, Executive Chairman
donaldkiepert@gmail.com
617-529-3243